“The increased risk for depression and anxiety that patients experience after a COVID-19 infection subsides after two months. But for up to two years, patients have an increased risk of psychiatric and neurological conditions.”
https://psychnews.psychiatryonline.org/doi/10.1176/appi.pn.2022.11.11.8?mibextid=Zxz2cZ
#COVID19 #longcovid #mentalhealth #health #medicine #neuroscience #psychology
Not 'for up to' but rather for 'at least'. Once that virus makes it across the BBB, it's there for good, so there's no reason to expect frequency to return to baseline. If anything, I'd expect ineluctable neurological decline.
We can probably put pressure on the rate of decline with antivirals and Complement Inhibitors, but it is important action is taken post haste.
The reason for my pessimism begins at 33:50, via the NIH:
This will be an NIH–FDA COVID-19 SIG lecture concerning findings from the NIH COVID-19 Autopsy Consortium. Daniel Chertow is a tenure-track investigator in the Critical Care Medicine Department at the NIH Clinical Center and in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases.<br><br>For more information go to <a href="https://www.niaid.nih.gov/research/covid-19-sig-lecture-series">https://www.niaid.nih.gov/research/covid-19-sig-lecture-series</a>
mark henick 
Shel 🌈
Laurie Bruno
J.H.Noyes